Transformational Epicenter
Medical-grade wellness meets luxury hospitality
Total Capital
$13.4M
5-Year Revenue
$125.5M
EBITDA Margin
8% → 70%
Y1 to Y5 expansion
MOIC (Base)
8.4x
IRR (Base)
74%
Y5 Enterprise Value
$229.3M
Sum-of-parts
Gross Margin
85%
The Opportunity
Transformational Epicenter sits at the convergence of four explosive growth markets, delivering medical-grade psychedelic therapy, bio-optimization, and luxury hospitality from a single integrated facility — the first of its kind at this scale.
Medical Tourism
$48-94B
Wellness Tourism
$850B+
Longevity Medicine
$27-33B
Psychedelic Therapy
$3-5B
Only facility integrating all four pillars
Financial Projections
5-Year P&L Summary
| Metric | Y1 | Y2 | Y3 | Y4 | Y5 |
|---|---|---|---|---|---|
| HC Revenue | $7.8M | $14.4M | $25.7M | $35.7M | $42.0M |
| HC EBITDA | $658K | $6.2M | $15.8M | $24.1M | $29.4M |
| Margin | 8% | 43% | 61% | 68% | 70% |
| HC Net Income | $-19,000 | $3.9M | $10.6M | $16.4M | $20.1M |
| Consol. Revenue | $7.8M | $15.5M | $28.6M | $40.7M | $48.2M |
| Consol. EBITDA | $658K | $7.1M | $18.1M | $28.1M | $34.2M |
Revenue Trajectory
Base case healing center revenue ($M)
Four Business Units
Healing Center
Clinical operations: ibogaine, psilocybin, 5-MeO-DMT, bio-optimization treatment programs
Y5 Revenue
$42.0M
Y5 EBITDA
$29.4M
Implied Value
$161.7M
Real Estate Development
48-villa condo-hotel plus $8.5M property appreciating at 5-10% annually
Property Base
$8.5M
Y5 Appreciated
$11.9M
Implied Value
$11.9M
Property Management
25% of villa rental revenue — recurring, contractual management fees
Y5 Revenue
$1.7M
Y5 EBITDA
$1.0M
Implied Value
$10.2M
Technology & Digital Platform
14 integrated systems generating proprietary clinical data — IP base plus per-patient-record data premium
4,436 Records
Y5 cumulative
Data Premium
$10K/record
Implied Value
$45.4M
Unit Economics
Revenue / Guest
$34,048
Direct Cost / Guest
$4,629
Gross Margin
86%
LTV : CAC
13.0x
Break-Even Occ.
~48%
203 guests/yr
Blended CAC
$2,613
Return Profile
Y5 Enterprise Value
$170.9M
MOIC
6.2x
IRR
65%
Y5 Enterprise Value
$229.3M
MOIC
8.4x
IRR
74%
Y5 Enterprise Value
$288.3M
MOIC
10.5x
IRR
85%
Use of Funds
Capacity & Phasing
Expansion funded from operating cash flow — no additional raise
Leadership
Nicholas Courchesne
Founder & CEO
Jason Sparks
Co-Founder & COO
Dan Lawless
Technical Lead
Dr. Mariana Hoyo
Chief Medical Advisor
Eyob Mebrahtu
Head of Marketing
Important Disclosures: This presentation is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any such offer will be made only by means of a confidential private placement memorandum and only to qualified investors in jurisdictions where permitted by law. Past performance is not indicative of future results. The projections and estimates contained herein involve significant elements of subjective judgment and analysis. Actual results may differ materially from those projected. Investment involves substantial risk, including the potential loss of principal.